Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Boring Dividend Stocks to Buy.
On November 18, Johnson & Johnson revealed that it plans to acquire privately held Halda Therapeutics for $3.05 billion in cash, a move intended to strengthen its position in therapies focused on solid tumors and prostate cancer. The purchase represents J&J’s second sizable transaction of the year, following its $14.6 billion takeover of Intra-Cellular Therapies in January, as the company continues shifting toward faster-growing areas of healthcare while managing the impact of losing exclusivity on Stelara, its top-selling immune disease drug.
Halda’s pipeline is led by HLD-0915, a prostate cancer therapy currently in early-to mid-stage clinical development. The company is also advancing several other experimental candidates targeting breast, lung, and various other tumor types.
In the previous month, Johnson & Johnson reported third-quarter revenue of $15.56 billion from its Innovative Medicine division, which includes oncology. That result topped analysts’ expectations of $15.42 billion, based on LSEG data.
Johnson & Johnson is a global healthcare company engaged in researching, developing, and producing a broad range of pharmaceuticals and medical technologies.
READ NEXT: 15 Best Long Term Stocks to Buy According to Reddit and 15 Best Stocks to Buy for Medium Term
